An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer

Anticancer Research

Volumn 20, Issue 3 B, 2000, Pages 1977-1984

  Gadducci, Angiolo ^a   Cosio, Stefania ^a   Fanucchi, Antonio ^a   Cristofani, Renza ^b   Genazzani, Andrea Riccardo ^a  

^a UNIVERSITY OF PISA   (Italy)

^b INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

Endometrial cancer; Follow up; Recurrence

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RECURRENCE; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; POSTOPERATIVE CARE; PRIORITY JOURNAL; THORAX RADIOGRAPHY; VAGINA SMEAR;

ACTUARIAL ANALYSIS; ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; EVALUATION STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYSTERECTOMY; LYMPHATIC METASTASIS; MIDDLE AGED; MYOMETRIUM; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PHYSICAL EXAMINATION; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; RISK; TREATMENT OUTCOME;

EID: 0033869055     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Mangioni C, De Palo G, Marubini E and Del Vecchio M: Surgical pathologic staging in apparent stage I endometrial carcinoma. Int J Gynecol Cancer 3: 373-384, 1993.
2. De Palo G, Mangioni C, Periti P, Del Vecchio M and Marubini E: Treatment of FIGO (1471) stage I endometrial carcinoma with intensive surgery, radiotherapy and hormonotherapy according to pathological prognostic groups. Long-term results of a randomised multicentre study. Eur J Cancer 29A: 1133-1140, 1993.
3. FIGO stages-1988 Revision (announcement). Gynecol Oncol 35: 125-127, 1989.
4. Gal D, Recio OF and Zamurovic D: The new International Federation of Gynecology and Obstetrics surgical staging and survival rates in early endometrial carcinoma. Cancer 69: 200-202, 1992.
5. Mikuta JJ: International Federation of Gynecology and Obstetrics staging of endometrial cancer 1988. Cancer 71: 1460-1463, 1993.
6. Lanciano RM, Corn BW, Schultz DJ, Kramer CA, Rosenblum N and Hogan WM: The justification for a surgical staging system in endometrial carcinoma. Radiother Oncol 28: 189-196, 1993.
7. Creasman W, Odicino F, Maisonneuve P, Benedet J, Shepherd J, Sideri M and Pecorelli S: Carcinoma of the corpus uteri. Annual report on the results of treatment in gynaecological cancer: twenty-third volume. J Epidemiol Biostat 3: 35-61, 1998.
8. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE and Heller PB. Surgical pathological spread patterns of endometrial cancer: A Gynecologie Oncology Group study. Cancer 60: 2035-2041, 1987.
9. Wilson TO, Podratz KC, Gaffey TA, Malkasian GD jr, O'Brien PC and Naessens JM: Evaluation of unfavorable histologie subtypes in endometrial adenocarcinoma. Am J Obstet Gynecol 162; 418-426, 1990.
10. Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD and Graham JE: Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A Gynecologic Oncology Group study. Gynecol Oncol 40: 55-65, 1991.
11. Lurain JR, Rice BL, Rademaker AW, Poggensee LE, Schink JC and Miller DS: Prognostic factors associated with recurrence in clinical stage I adenocarcinoma of the endometrium. Obstet Gynecol 78: 63-69, 1991.
12. Shumsky AG, Brasher PMA, Stuart GCE and Nation JG: Risk-specific follow-up for endometrial carcinoma patients. Gynecol Oncol 65: 379-382, 1997.
13. Salvesen HB, Iversen OE and Akslen LA: Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: A population-based endometrial carcinoma study. J Clin Oncol 17: 1382-1390, 1999.
14. Lim P, Aquino-Parsons CF, Wong F, Dupuis B, Phillips D, Zhou C and Gilks CB: Low-risk endometrial carcinoma: Assessment of a treatment policy based on tumor ploidy and identification of additional prognostic indicators. Gynecol Oncol 73: 191-195, 1999.
15. Cochrane JP, Williams JT, Faber RG and Slack WW: Value of outpatient follow-up after curative surgery for carcinoma of the large bowel. BMJ 280: 593-595, 1980.
16. Rosselli Del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P and Distante V: Intensive diagnostic follow-up after treatment of primary breast cancer: A randomized trial. J Am Med Assoc 271: 1593-1597, 1994.
17. Burke TW: How should we monitor women treated for endometrial carcinoma? Gynecol Oncol 65: 377-378, 1997 (editorial).
18. Barnhill D, O'Connor D, Farley J, Teneriello M, Armstrong D and Park R: Clinical surveillance of gynecologic cancer patients. Gynecol Oncol 46: 275-280, 1992.
19. Podczaski E, Kaminski P, Gurski K, MacNeill C, Stryker JA, Singapuri K, Hackett TE, Sorosky J and Zaino R: Detection and pat terns of treament failure in 300 consecutive cases of "early" endometrial cancer after primary surgery. Gynecol Oncol 47: 323-327, 1992.
20. Shumsky AG, Stuart GCE, Brasher P, Nation JG, Robertson DI and Sangkarat S: An evaluation of routine follow-up of patients treated for endometrial carcinoma. Gynecol Oncol 55: 229-233, 1994.
21. Berchuck A, Anspach C, Evans AC, Soper JT, Rodriguez GC, Dodge R, Robboy S and Clarke-Pearson DL: Postsurgical surveillance of patients with FIGO stage I/II endometrial adenocarcinoma. Gynecol Oncol 59: 20-24, 1995.
22. Reddoch JM, Burke TW, Morris M, Tornos C, Levenback C and Gershenson DM: Surveillance for recurrent endometrial carcinoma: Development of a follow-up scheme. Gynecol Oncol 59: 221-225, 1915.
23. Owen P and Duncan ID: Is there any value in the long term follow-up of women treated for endometrial carcinoma? Br J Obstet Gynaecol 103: 710-713, 1996.
24. Salvesen HB, Akslen LA, Iversen T and Iversen OE: Recurrence of endometrial carcinoma and the value of routine follow up. Br J Obstet, Gvnaecol 104: 1302-1307, 1997.
25. Agboola OO, Grunfeld E, Coyle D and Perry GA: Costs and benefits of routine follow-up after curative treatment for endometrial cancer. CMAJ 157: 879-886, 1997.
26. Corn BW, Lanciano RM, D'Agostino R Jr, Kiggundu E, Dunton CJ, Pursen P and Greven KM: The relationship of local and distant failure from endometrial cancer: Defining a clinical paradigm. Gynecol Oncol 66: 411-416, 1997.
27. Grigsby PW, Perez CA, Kuten A, Simpson JR, Garcia DM, Camel HM, Kao MS and Galakatos AE: Clinical stage I endometrial cancer: Prognostic factors for local control and distant metastasis and implications of the new FIGO surgical staging system. Int J Radiat Oncol Biol Phys 22: 905-911, 1992.
28. Aalders J, Abeler V, Kolstad P and Onsrud M: Postoperative external irradiation and prognostic parameters in Stage I endometrial carcinoma. Obstet Gynecol 56: 419-426, 1980.
29. DiSaia PJ and Creasman WT. Adenocarcinoma of the uterus. In: "Clinical gynecologic oncology" 5th ed. St Louis: Mosby, 1997, pp. 134-167.
30. Irwin C, Lewin W, Fyles A, Pintilie M, Manchul L and Kirkbride P: The role of adjuvant radiotherapy in carcinoma of the endometrium-results in 550 patients with pathologic stage 1 disease. Gynecol Oncol 70:247-254, 1998.
31. Homesley HD: Management of endometrial cancer Am J Obstet Gynecol 174: 529-534, 1996.
32. Maggino T, Romagnolo C, Zola P, Sartori E, Landoni F and Gadducci A: An analysis of approaches to the treatment of endometrial cancer in Western Europe: A CTF study. Eur J Cancer 31A: 1993-1997, 1995.
33. Ackerman I, Malone S, Thomas G, Franssen E, Balogh J and Dembo A: Endometrial carcinoma-relative effectiveness of adjuvant irradiation vs therapy reserved for relapse. Gynecol Oncol 60: 177-183, 1996.
34. Pai HH, Souhami L, Clark BG and Roman T Isolated vaginal recurrences in endometrial carcinoma: Treatment results using highdose-rate intracavitary brachytherapy and external beam radiotherapy. Gynecol Oncol 66: 300-307, 1997.
35. Hart KB, Han I, Shamsa F, Court WS, Chuba P, Deppe G, Malone J, Christensen C and Porter AT: Radiation therapy for endometrial cancer in patients treated for postoperative recurrence. Int J Radiat Oncol Biol Phys 41: 7-11, 1998.
36. Lovecchio JL, Averette HE, Lichtinger M, Townsend PA, Girtanner RW, and Fenton AN: Treatment of advanced or recurrent endometrial adenocarcinoma with cyclophosphamide, doxorubicin, cis-platinum, and megestrol acetate. Obstet Gynecol 63: 557-560, 1984.
37. Edmondson JH, Krook JE, Hilton JF, Malkasian GD, Everson LK, Jeffries JA and Maillard JA: Randomized phase II studies of cisplatin and a combination of cyclophosphamide-doxorubicin-cisplatin (CAP) in patients with progestin-refractory advanced endometrial carcinoma. Gynecol Oncol 28: 20-24, 1987.
38. Dunton CJ, Pfeifer SM, Braitman LE, Morgan MA, Carlson JA, and Mikuta JJ: Treatment of advanced and recurrent endometrial cancer with cisplatin, doxorubicin and cyclophosphamide. Gynecol Oncol 41: 113-166, 1991.
39. Burke TW, Stringer CA, Morris M, Freedman RS, Gershenson DM, Kavanagh JJ and Edwards CL: Prospective treatment of advanced or recurrent endometrial carcinoma with cisplatin, doxorubicin, and cyclophosphamide. Gynecol Oncol 40: 264-267, 1991.
40. Thigpen T, Vance RB and Khansur Y: The platinum compounds in the management of carcinomas of the endometrium and uterine cervix. Semin Oncol 22 (Suppl. 12): 67-75, 1995.
41. Gadducci A, Romanini A, Cosio S, Fanucchi A, Tanganelli L, Ciampi B and Genazzani AR: Combination of cisplatin, epirubicin, and cyclophosphamide (PEC regimen) in advanced or recurrent endometrial cancer: A retrospective clinical study. Anticancer Res 19: 2253-2256, 1999.
42. Ball HG, Blessing JA, Lentz SS and Mutch DG: A phase II trial of taxol in advanced and recurrent adenocarcinoma of the endometrium. Gynecol Oncol 62: 278-281, 1996.
43. Lissoni A, Zanetta G, Losa G, Gabriele A, Parma G and Mangioni C: Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer. Ann Oncol 7: 861-863, 1996.
44. Fleming GF, Fowler JM, Waggoner BS, Greer BE, Schilder RJ, Ball HG and McGuire III WP: Phase I trial of escalating doses of paclitaxel (TAX) combined with fixed doses of cisplatin (cis) and doxorubicin (DOX) in patients with advanced gynecologic malignancies: A Gynecologic Oncology Group study. Proc Am Soc Clin Oncol 17: 361, 1998 (Abstract 1393).